{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:09:50Z","timestamp":1761894590461},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,9,7]],"date-time":"2007-09-07T00:00:00Z","timestamp":1189123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,9,7]],"date-time":"2007-09-07T00:00:00Z","timestamp":1189123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s12016-007-8020-7","type":"journal-article","created":{"date-parts":[[2007,9,10]],"date-time":"2007-09-10T23:29:06Z","timestamp":1189466946000},"page":"103-110","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Rituximab Off Label Use for Difficult-To-Treat Auto-Immune Diseases: Reappraisal of Benefits and Risks"],"prefix":"10.1007","volume":"34","author":[{"given":"Laurent","family":"Sailler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,9,7]]},"reference":[{"key":"8020_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1160\/TH06-06-0317","volume":"96","author":"M Franchini","year":"2006","unstructured":"Franchini M et al (2006) The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 96:119\u2013125","journal-title":"Thromb Haemost"},{"key":"8020_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","volume":"31","author":"E Kimby","year":"2005","unstructured":"Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456\u2013473","journal-title":"Cancer Treat Rev"},{"key":"8020_CR3","first-page":"72","volume":"90","author":"N Vianelli","year":"2005","unstructured":"Vianelli N et al (2005) Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 90:72\u201377","journal-title":"Haematologica"},{"key":"8020_CR4","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","volume":"107","author":"CM Bennett","year":"2006","unstructured":"Bennett CM et al (2006) Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107:2639\u20132642","journal-title":"Blood"},{"key":"8020_CR5","first-page":"99","volume":"27","author":"MN Saleh","year":"2000","unstructured":"Saleh MN et al (2000) A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27:99\u2013103","journal-title":"Semin Oncol"},{"key":"8020_CR6","doi-asserted-by":"crossref","unstructured":"Godeau B et al (2006) Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase 2 study. Blood 108,145a, abstract 478.","DOI":"10.1182\/blood.V108.11.478.478"},{"key":"8020_CR7","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","volume":"104","author":"K Kojouri","year":"2004","unstructured":"Kojouri K et al (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104:2623\u20132634","journal-title":"Blood"},{"key":"8020_CR8","first-page":"281","volume":"90","author":"T Taube","year":"2005","unstructured":"Taube T et al (2005) Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 90:281\u2013283","journal-title":"Haematologica"},{"key":"8020_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ajh.20665","volume":"81","author":"G D\u2019Arena","year":"2006","unstructured":"D\u2019Arena G et al (2006) Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 81:598\u2013602","journal-title":"Am J Hematol"},{"key":"8020_CR10","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1080\/1042819031000119235","volume":"44","author":"F Zaja","year":"2003","unstructured":"Zaja F et al (2003) Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 44:1951\u20131955","journal-title":"Leuk Lymphoma"},{"key":"8020_CR11","first-page":"1273","volume":"90","author":"S Narat","year":"2005","unstructured":"Narat S et al (2005) Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 90:1273\u20131274","journal-title":"Haematologica"},{"key":"8020_CR12","first-page":"223","volume":"88","author":"G Trape","year":"2003","unstructured":"Trape G et al (2003) Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 88:223\u2013225","journal-title":"Haematologica"},{"key":"8020_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.4065\/78.11.1340","volume":"78","author":"TD Shanafelt","year":"2003","unstructured":"Shanafelt TD et al (2003) Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 78:1340\u20131346","journal-title":"Mayo Clin Proc"},{"key":"8020_CR14","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","volume":"101","author":"M Zecca","year":"2003","unstructured":"Zecca M et al (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857\u20133861","journal-title":"Blood"},{"key":"8020_CR15","first-page":"460","volume":"91","author":"S Berentsen","year":"2006","unstructured":"Berentsen S et al (2006) Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 91:460\u2013466","journal-title":"Haematologica"},{"key":"8020_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/10428190500286481","volume":"47","author":"C Schollkopf","year":"2006","unstructured":"Schollkopf C et al (2006) Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 47:253\u2013260","journal-title":"Leuk Lymphoma"},{"key":"8020_CR17","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","volume":"103","author":"S Berentsen","year":"2004","unstructured":"Berentsen S et al (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103:2925\u20132928","journal-title":"Blood"},{"key":"8020_CR18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"M Tokunaga","year":"2004","unstructured":"Tokunaga M et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470\u2013475","journal-title":"Ann Rheum Dis"},{"key":"8020_CR19","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1186\/ar2076","volume":"8","author":"T Vallerskog","year":"2006","unstructured":"Vallerskog T et al (2006) Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8:R167","journal-title":"Arthritis Res Ther"},{"key":"8020_CR20","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","volume":"44","author":"MJ Leandro","year":"2005","unstructured":"Leandro MJ et al (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44:1542\u20131545","journal-title":"Rheumatology (Oxford)"},{"key":"8020_CR21","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG et al (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970\u20132982","journal-title":"Arthritis Rheum"},{"key":"8020_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jpeds.2006.01.041","volume":"148","author":"M Willems","year":"2006","unstructured":"Willems M et al (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623\u2013627","journal-title":"J Pediatr"},{"key":"8020_CR23","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez M et al (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83","journal-title":"Arthritis Res Ther"},{"key":"8020_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP et al (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52:501\u2013513","journal-title":"Arthritis Rheum"},{"key":"8020_CR25","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1002\/art.21351","volume":"52","author":"SD Marks","year":"2005","unstructured":"Marks SD et al (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168\u20133174","journal-title":"Arthritis Rheum"},{"key":"8020_CR26","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580\u20132589","journal-title":"Arthritis Rheum"},{"key":"8020_CR27","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"JE Gottenberg","year":"2005","unstructured":"Gottenberg JE et al (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913\u2013920","journal-title":"Ann Rheum Dis"},{"key":"8020_CR28","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219\u20132228","journal-title":"N Engl J Med"},{"key":"8020_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror R et al (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66:351\u2013357","journal-title":"Ann Rheum Dis"},{"key":"8020_CR30","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe J et al (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52:2740\u20132750","journal-title":"Arthritis Rheum"},{"key":"8020_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study Arthritis Rheum 52:601\u2013607","journal-title":"Arthritis Rheum"},{"key":"8020_CR32","first-page":"1021","volume":"33","author":"EH Noss","year":"2006","unstructured":"Noss EH et al (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33:1021\u20131026","journal-title":"J Rheumatol"},{"key":"8020_CR33","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","volume":"45","author":"R Stasi","year":"2006","unstructured":"Stasi R et al (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45:1432\u20131436","journal-title":"Rheumatology (Oxford)"},{"key":"8020_CR34","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/ard.2005.044420","volume":"65","author":"PM Aries","year":"2006","unstructured":"Aries PM et al (2006) Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853\u2013858","journal-title":"Ann Rheum Dis"},{"key":"8020_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","volume":"173","author":"KA Keogh","year":"2006","unstructured":"Keogh KA et al (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180\u2013187","journal-title":"Am J Respir Crit Care Med"},{"key":"8020_CR36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","volume":"257","author":"P Eriksson","year":"2005","unstructured":"Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540\u2013548","journal-title":"J Intern Med"},{"key":"8020_CR37","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","volume":"101","author":"D Sansonno","year":"2003","unstructured":"Sansonno D et al (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818\u20133826","journal-title":"Blood"},{"key":"8020_CR38","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","volume":"19","author":"D Roccatello","year":"2004","unstructured":"Roccatello D et al (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19:3054\u20133061","journal-title":"Nephrol Dial Transplant"},{"key":"8020_CR39","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja F et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827\u20133834","journal-title":"Blood"},{"key":"8020_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3816\/CLM.2006.n.052","volume":"7","author":"AH Bryce","year":"2006","unstructured":"Bryce AH et al (2006) Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 7:140\u2013144","journal-title":"Clin Lymphoma Myeloma"},{"key":"8020_CR41","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.transproceed.2006.06.131","volume":"38","author":"G Basse","year":"2006","unstructured":"Basse G et al (2006) Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 38:2308\u20132310","journal-title":"Transplant Proc"},{"key":"8020_CR42","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1182\/blood-2006-08-041525","volume":"109","author":"G Lake-Bakaar","year":"2007","unstructured":"Lake-Bakaar G et al (2007) Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109:845\u2013846","journal-title":"Blood"},{"key":"8020_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","volume":"31","author":"E Schmidt","year":"2006","unstructured":"Schmidt E et al (2006) Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 31:503\u2013508","journal-title":"Clin Exp Dermatol"},{"key":"8020_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","volume":"156","author":"E Schmidt","year":"2007","unstructured":"Schmidt E et al (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156:352\u2013356","journal-title":"Br J Dermatol"},{"key":"8020_CR45","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","volume":"355","author":"AR Ahmed","year":"2006","unstructured":"Ahmed AR et al (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772\u20131779","journal-title":"N Engl J Med"},{"key":"8020_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1365-2141.2005.05512.x","volume":"129","author":"M Bohm","year":"2005","unstructured":"Bohm M et al (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 129:644\u2013652","journal-title":"Br J Haematol"},{"key":"8020_CR47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","volume":"136","author":"M Scully","year":"2007","unstructured":"Scully M et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136:451\u2013461","journal-title":"Br J Haematol"},{"key":"8020_CR48","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","volume":"106","author":"F Fakhouri","year":"2005","unstructured":"Fakhouri F et al (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932\u20131937","journal-title":"Blood"},{"key":"8020_CR49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1160\/TH06-09-0499","volume":"97","author":"F Heidel","year":"2007","unstructured":"Heidel F et al (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97:228\u2013233","journal-title":"Thromb Haemost"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-007-8020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-007-8020-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-007-8020-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-007-8020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:02:05Z","timestamp":1659092525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-007-8020-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["8020"],"URL":"https:\/\/doi.org\/10.1007\/s12016-007-8020-7","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,7]]},"assertion":[{"value":"7 September 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}